PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune ...

T-cell-specific surface glycoprotein CD28, also known as TP44, is a single-pass type I membrane protein that contains one Ig-like V-type (immunoglobulin-like) domain. It is a key co-stimulatory ...

Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of ...

Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course ...

The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies to treat ...

Cancer is a notoriously complex monster; hydra-like in its ability to seemingly grow new heads with each one severed. Although significant progress has been made in the development of oncologic ...

– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers ...